Nature Medicine, Published online: 15 April 2024; doi:10.1038/s41591-024-02886-y
An exploratory analysis of the 1-year clinical trial PASADENA in individuals with early-stage Parkinson’s disease suggests that prasinezumab might reduce motor signs progression to a greater extent in those with more rapidly progressing disease.
Comments
No Trackbacks.